BLUJEPA (Gepotidacin Mesylate) Patent Expiration, LOE Window & CMS Spending

BLUJEPA (Gepotidacin Mesylate) by GSK: FDA Orange Book core substance LOE 2042-12-13, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN218230 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2042-12-13
Last Listed Patent or Exclusivity Date2042-12-13
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,900 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.